BCI translation expands from prototypes toward clinical and commercial adoption

Neuracle's regulatory-insurance pairing, CorTec's FDA Breakthrough Device designation, Phosphoenix's €1.3 million raise, and Utah's first at-home LUKE Arm trial show momentum across clinical infrastructure, investment, and everyday use. The signals remain early: the LUKE Arm evidence is limited to one participant, while patient outcomes, safety, durability, regulatory scope, and independent validation remain uncertain.